Plots of effects of anti-MIP-2 MAb treatment on survival in mice with EMC viral myocarditis. C3H/He mice were infected subcutaneously with anti-MIP-2 MAb on days 0 to 5 and were observed until day 21. Significant increases (P < 0.05) in survival were found in the anti-MIP-2 MAb group (group 3; ■) in comparison with the controls (group 1; ○). ○, group 1, control; ●, group 2, anti-MIP-2 at 10 μg/day; ■, group 3, anti-MIP-2 at 100 μg/day.